Cavalry Fund I LP 13D and 13G filings for Biodexa Pharmaceuticals Plc:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-07 4:51 pm Sale |
2024-09-30 | 13G | Biodexa Pharmaceuticals Plc BDRX |
Cavalry Fund I LP | 0 0.000% |
-4,647,807 (Position Closed) |
Filing |
| 2024-02-13 4:33 pm Purchase |
2023-12-31 | 13G | Biodexa Pharmaceuticals Plc BDRX |
Cavalry Fund I LP | 4,647,807 9.900% |
225,487 (+5.10%) |
Filing |
| 2023-12-28 4:30 pm Purchase |
2023-12-21 | 13G | Biodexa Pharmaceuticals Plc BDRX |
Cavalry Fund I LP | 4,422,320 9.900% |
4,422,320 (New Position) |
Filing |